







an Open Access Journal by MDPI

# **Stem Cell Therapy for Cerebrovascular Disease**

Guest Editors:

## Dr. Zhonglin Lyu

Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, CA 94305, USA

### **Dr. Shang Song**

Department of Biomedical Engineering, University of Arizona, Tucson, AZ 85721, USA

Deadline for manuscript submissions:

closed (30 December 2022)

## **Message from the Guest Editors**

This Special Issue focuses on the most recent advances in stem cell therapy for cerebrovascular disease. Of special interest are manuscripts (both original articles and reviews) addressing topics include but not limited to:

- Mechanism of action of stem cell in cerebrovascular disease
- Approaches for the preparation of adequate number and high quality of stem cell for transplantation.
- Novel 3D bioprocessing techniques that facilitate the clinical translation of stem cell therapy.
- Novel bioengineered cell-free stem cells mimics for cerebrovascular disease recovery.
- Novel biomaterials that facilitates stem cell therapy.
- In vitro 3D organ models that advances stem cell therapy.













an Open Access Journal by MDPI

## **Editor-in-Chief**

### Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank: JCR - Q2 (Engineering, Biomedical)

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

#### **Contact Us**

*Bioengineering* Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland

Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/bioengineering bioengineering@mdpi.com X@Bioeng\_MDPI